Foreign enterprises to take the "Great Retreat", forced enterprise transformation you are ready?

Guide: In-depth national harvest, how do foreign-funded enterprises move forward? As a result of the publication of the third batch of shortlists, 186 enterprises to run, 125 enterprises to be selected, of which only 3 original research enterprises have products winning the bid, causing discussion in the pharmaceutical industry, foreign enterprises will face a "great retreat"? There are foreign enterprise management personnel vaguely worried, the third batch of mining companies in the list of large varieties, both middle and not, will be broken bones.
Pfizer regional manager is very helpless, although Shishumei did not enter the second batch of collection list, but three years later Shishumei and set Achimycin price of 5.46 yuan, how long can we survive? Noor and Nord's senior product managers are becoming more insecure, metformin is a penny, how long can we No. These are real scenes, a century of global change, outbreaks of 2020, foreign medicine people worry.
a middle-class foreign company, through the 35-year-old middle-aged crisis, but can not cross the river.
1 cent of metformin, once again refresh the lower cognitive limit of medical people, is the same kind of Gwark is so bad? Just a penny.
indeed, the truth is more serious than you think.
foreign companies come to China and retreat, is it just good? From the first foreign enterprises to date, has more than 30 years of history, foreign enterprises are a microcosm of China's economic development.
the beginning of china's reform and opening-up, multinational pharmaceutical companies have entered China with technology exchanges as the starting point.
, the sales amount of foreign pharmaceutical companies with China's economic development, a blowout rise, foreigners see China as a place of gold everywhere.
Pfizer's China revenue of $2.57 billion in 2019, or 26% of the world's total, is one of the "China-benefiting" multinational drug companies, while AstraZeneta's sales in China have tripled in a decade, according to data.
's time to leave, two years ago, GlaxoSmithKline's Central Nervous System Research and Development Center, which was notified by its headquarters, would close by the end of November, while Lilly announced it would close its research and development center in Zhangjiang, Shanghai.
foreign pharmaceutical companies have scaled back their investment strategies in China, proving once again that China's cake is no longer easily divided.
high labor costs, preferential policies no longer have advantages, the most important thing is that China's medical reform in-depth, the policy refers directly to foreign pharmaceutical companies.
the head of government affairs of a foreign-funded pharmaceutical company said that enterprises are most concerned not with access to health insurance, but with which products enter the collection.
01 collection list continues to expand, until the scope of all collection of drugs gradually expanded, non-patented drugs all into the collection is the trend.
The author of an expert involved in the evaluation of the discussion, experts believe that: the current consistency evaluation for enterprises to bear a heavy burden, the current consistency evaluation work is a supplement to the previous lesson, is an authentic source of the pharmaceutical industry project;
the corresponding collection work with the arrival of the normal mechanism, the list of drugs included in the collection will be further expanded, and even more so, all varieties into the collection.
With the normalization of the volume of procurement into a final decision, if multinational pharmaceutical companies continue to take the attitude of giving up the market, the varieties not entering the collection means the amount of loss, has been picked, has been lost, or until the end of the loss.
02 The share of generic drugs is too large generic drugs are named after the original drug has been the consensus of the industry; Foreign companies in the hype of the concept of the original drug research, while sitting on this part of the concept of dividends, from another point of view, foreign companies in the strategic slack, especially in China's introduction of new drugs.
overall revenue, the proportion of original research drugs is too large, once encountered, turn around is so difficult.
Pfizer is a case, too many patented original research drugs into the collection, including more than 20 well-known products, involving cardiovascular, pain, psychiatry and urology and other noncommunicable diseases treatment field, mainly for the patent period of mature original research drug products, such as Liputo, Live Hi, Wan Aico and so on.
2018 sales of 10 billion yuan, accounting for 68% of the country's sample hospital sales, more than a third of Pfizer's total sales in China, according to data from the company.
, Pfizer is strong against the dependence of products such as Puto.
does that mean? A cliff in drug patents is coming.
is not only a challenge for Pfizer, but for almost every drug company, but Pfizer is under pressure from the entire Pfizer group.
03 Patented drugs encounter medical insurance negotiations access foreign pharmaceutical enterprises mission is mostly to save human life or health as their own responsibility, originally hoped that in the patent period innovative drugs successful commercial operation, do not know the encounter with Chinese characteristics of innovative medical reform, patent drugs into the medical insurance process, the implementation of negotiations access, essentially is to reduce prices.
that patented drugs are cheaper than the world's lowest prices and can be covered.
, the last potential stocks of foreign pharmaceutical companies have stalled in China.
ever, foreign pharmaceutical companies research and development pipeline products listed in China, rarely synchronized with the world, along with the collection of further comprehensive normal in-depth, in the future, foreign pharmaceutical companies in China or even more difficult.
foreign pharmaceutical companies also need to be in the end, in the cloud.
down and walked into the world.
to regain the fireworks, foreign pharmaceutical companies need to start from the lower body to abolish.
01 marketing costs move tens of millions, down! Although the era of drug marketing-driven has passed, now pay more attention to medical education and medical value reconstruction, but there are still many enterprises hope to improve performance through large-scale marketing activities, in the country's top-level design and hospital floor expenditure control under the double blow, marketing results are very small, and ultimately huge marketing expenses, lost mrs.
02 personnel costs casually will be millions, down! Staff costs have been criticized in the operation of foreign enterprises, personnel costs remain high, for foreign enterprises operating in China on the burden.
labor costs and individual labor costs are maintained at a high level, such as sales director, foreign enterprises generally open to 1 million, domestic enterprises are 60-70 million, 30% higher.
In addition, the price of personnel of foreign enterprises is also relatively redundant, to enterprise market access examples, central government access, responsible for health insurance, basic drugs, collection, health, industry and information, and so on, also need a market access strategy, need so many people? 03 Travel access to five-star, the cost is too high, down! Many foreign companies have so far retained the chinese pharmaceutical market's high-growth dividend business model, making its operating costs remain high.
have an external leader who says, "If you're not an Air China or a Gold Card, it means your job isn't in place."
" is such a mode of thinking, creating foreign enterprises should be high cost, so many disadvantages.
high operating costs, which carry a heavy operating burden on the business, especially in the travel section, and even some product managers are already platinum cards, these can be the company's blood.
some foreign companies have taken steps to rank the top 10 "flyers" and "eaters" to reflect the company's focus on operations, but with little success, the real solution is linked to KPIs.
04 Access to super-national treatment, flat! It's time for consistency.
the advantages of foreign pharmaceutical companies in registration, pricing and access are still unmatched, but with the promotion of healthy China 2030 plan and the deepening of medical reform, the super-national treatment of foreign enterprises will soon be.
Early in the patent period, foreign enterprises enjoy unique pricing power, after the patent, and then to the original drug different quality levels, with priority pricing power, and now finally to be consistent, which is a good for domestic pharmaceutical companies, especially in terms of pricing.
In addition, access to foreign enterprises also has many advantages, Roche last year access to a number of cancer drugs, Novarma access to 11 products, although it reflects Roche Pharmaceutical's strong research and development strength, with the national anti-tumor drugs, but at the same time from the side reflects the foreign enterprises enjoy the super-national treatment in China.
It is true that foreign pharmaceutical companies in promoting China's pharmaceutical market and international standards have an unstoppable credit, but its long-term super-national treatment, has caused some resistance to the healthy development of China's pharmaceutical market, only three down one flat, can quickly promote the localization of foreign pharmaceutical enterprises, the limit into a life-saving.
well-known vice president of domestic pharmaceutical companies and foreign medical managers equal pay, travel fast, enterprise marketing costs reduced again and again, imagine, foreign pharmaceutical companies in the cost-leading strategy of how competitive? But these will change with the collection, China has no foreign and domestic pharmaceutical companies, only patented pharmaceutical companies and non-patent pharmaceutical enterprises.
you ready to transform before foreign pharmaceutical companies are about to struggle or leave China?